PreludeDx Announces New Response Type Biosignature Data at the 37th Annual Miami Breast Cancer Conference

New Response Type™ Biosignature Identifies Women at Elevated Risk of Recurrence after Surgery and Radiation Therapy for DCIS DCISionRT integration into decision-making changed treatment recommendations in 45% of women with DCIS Prospective Trial near... Diagnostics, Oncology PreludeDx, DCISionRT, ductal carcinoma, breast cancer, DCIS
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news